582 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Purchased by Family Firm Inc.

Family Firm Inc. purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 582 shares of the medical research company’s stock, valued at approximately $80,000.

Other hedge funds also recently bought and sold shares of the company. Louisiana State Employees Retirement System bought a new position in Quest Diagnostics during the 4th quarter valued at about $938,000. Lindbrook Capital LLC lifted its stake in Quest Diagnostics by 120.7% during the 4th quarter. Lindbrook Capital LLC now owns 415 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 227 shares during the period. Signaturefd LLC lifted its stake in Quest Diagnostics by 43.7% during the 4th quarter. Signaturefd LLC now owns 1,374 shares of the medical research company’s stock valued at $189,000 after acquiring an additional 418 shares during the period. CWM LLC lifted its stake in Quest Diagnostics by 1.3% during the 4th quarter. CWM LLC now owns 18,200 shares of the medical research company’s stock valued at $2,509,000 after acquiring an additional 232 shares during the period. Finally, GAMMA Investing LLC bought a new position in Quest Diagnostics during the 4th quarter valued at about $67,000. Institutional investors own 88.06% of the company’s stock.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total transaction of $60,093.60. Following the completion of the transaction, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.79% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Quest Diagnostics from $152.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, May 30th. Citigroup upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $145.00 to $165.00 in a research note on Wednesday, July 10th. StockNews.com upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 23rd. Truist Financial boosted their price target on Quest Diagnostics from $150.00 to $158.00 and gave the company a “hold” rating in a report on Monday, July 15th. Finally, Robert W. Baird upped their price target on Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $150.58.

Quest Diagnostics Stock Up 0.5 %

NYSE DGX opened at $153.56 on Friday. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $153.81. The company has a current ratio of 1.00, a quick ratio of 0.91 and a debt-to-equity ratio of 0.57. The stock has a market cap of $17.06 billion, a PE ratio of 20.67, a P/E/G ratio of 2.69 and a beta of 0.89. The stock’s 50 day moving average is $144.29 and its 200 day moving average is $136.96.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.30 earnings per share. Research analysts predict that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $3.00 annualized dividend and a dividend yield of 1.95%. Quest Diagnostics’s dividend payout ratio (DPR) is 40.38%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.